PRINCETON, N.J., and PARIS, May 24, 2010 — Stentys announced that it has received CE Marking for its drug-eluting self-expanding stent.
The unique self-expanding Stentys stent is designed to ensure optimal apposition of a stent in the critical initial hours and days after an AMI (acute myocardial infarction) procedure, by being continuously applied to the vessel‟s internal wall even during thrombus resolution and vessel spasm relief—thereby avoiding malapposition, a major predictor of stent thrombosis...
...About Stentys
Based in Princeton, N.J., and Paris, Stentys intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. The Company announced in December 2009 that it has started enrolling patients in the randomized APPOSITION II clinical trial to compare the Stentys self expanding stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth... [PDF] Stentys' Press Release -
Blog Archive
-
▼
2010
(51)
-
▼
June
(7)
- Protea Biosciences and Mayoly-Spindler : Human Cli...
- Rhenovia's Epilepsy Program for the Optimization o...
- Transgene : exclusive option agreement for the dev...
- Stentys' drug-eluting self-expanding stent : CE Ma...
- IntegraGen : publication of the Results of a Study...
- Vaxon Biotech successfully completes its Phase I/I...
- Arterial Remodeling Technologies : data from in vi...
-
▼
June
(7)